Arrowhead Pharmaceuticals Inc. (ARWR)
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 61.48 0.00%
ARWR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.68B
- EPS (TTM)
- -$2.28
- Dividend yield
- None
- 52-week range
- 34.61 – 95.49
- Day range
- 60.78 – 62.75
- Volume / Avg
- 1.82M / 1.90M
- Beta
- —
- Shares outstanding
- 141.25M
52-week range
ARWR stock today
Arrowhead Pharmaceuticals (ARWR) closed at $61.48 on Oct 7, down 0.10% (-$0.06), versus the S&P 500's 0.22% decline. At this level, ARWR sits in the middle of its 52-week range of $34.61 to $95.49: 35.6% below the high, set on Jul 22, 2026 and 77.6% above the low. ARWR is down 7.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 68.3%.
Arrowhead Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.28), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Arrowhead Pharmaceuticals
Company profileArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christopher R. Anzalone Ph.D.
- Headquarters
- Pasadena, CA
- Employees
- 711
- Website
- arrowheadpharma.com
Financial highlights
Full financialsIn fiscal 2025, Arrowhead Pharmaceuticals generated $829.4 million in revenue, up 23258.2% from fiscal 2024. Arrowhead Pharmaceuticals reported a net loss of $1.6 million, compared with a loss of $599.5 million a year earlier. Operating margin was 11.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $829.45M | $3.55M | $240.74M | $243.23M | $138.29M |
| Growth | +23258.15% | -98.52% | -1.03% | +75.89% | +57.16% |
| Net income | $-1.63M | $-599.49M | $-205.28M | $-176.06M | $-140.85M |
| EPS (diluted) | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$107.23+74.41%
- Strong buy 4
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q3 2026)
- Aug 4, 2026
- EPS actual vs est.
- $-1.36 vs —
Arrowhead Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs ARWR |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs ARWR |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs ARWR |
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs ARWR |
| PRAXPraxis Precision Medicines Inc. | 278.02 | -0.76% | $7.76B | vs ARWR |
| ABVXAbivax SA ADR | 87.01 | -1.37% | $7.59B | vs ARWR |
| IONSIonis Pharmaceuticals Inc. | 44.16 | +0.36% | $7.34B | vs ARWR |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs ARWR |
Indexes, lists and sector
Arrowhead Pharmaceuticals stock FAQ
What is Arrowhead Pharmaceuticals's stock price today?
ARWR last traded at $61.48 as of Oct 7, 4:00 PM EDT, down 0.10% on the day. Prices are delayed at least 15 minutes.
Does Arrowhead Pharmaceuticals pay a dividend?
No. Arrowhead Pharmaceuticals does not currently pay a regular cash dividend.
Who is Arrowhead Pharmaceuticals's CEO?
Dr. Christopher R. Anzalone Ph.D. is the chief executive officer of Arrowhead Pharmaceuticals Inc., which has about 711 employees.
Has ARWR ever split its stock?
Yes. The most recent ARWR stock split was a 1-for-10 split on Nov 17, 2011, one of 2 splits on record.
What is the ARWR 52-week high?
The 52-week high for ARWR is $95.49 and the 52-week low is $34.61. The stock is currently 35.6% below its high.